North America Anatomic Pathology Market Size, Share & Trends Analysis, 2025-2035
The North America Anatomic Pathology Market is poised for substantial growth, driven by rising incidences of chronic diseases, a surge in cancer diagnostics, and ongoing technological advancements in pathology. The market encompasses a broad spectrum of products and services, such as instruments, consumables, services, reagents, and kits, which are essential to disease diagnosis, research, and drug development processes. The growing adoption of molecular pathology, digitization of laboratory workflows, and increasing preference for automation further propel market expansion. Additionally, supportive regulatory environments, strategic collaborations, and a highly developed healthcare infrastructure provide a fertile landscape for market players. However, certain challenges like skilled personnel shortages and high equipment costs could somewhat restrain market growth.
Latest Market Dynamics
Key Drivers
- Growing prevalence of cancer and chronic diseases—With rising incidences of cancer in North America, there is an escalating need for precise diagnostic techniques which is fueling the demand for advanced anatomic pathology solutions. For example, Thermo Fisher Scientific recently expanded its pathology reagent portfolio in response to increased cancer screening volumes.
- Advancements in digital pathology—The integration of artificial intelligence and digital imaging solutions is improving diagnostic accuracy and workflow efficiency. In June 2024, Roche launched an advanced AI-enabled digital pathology platform to enhance tissue analysis for clinical labs.
Key Trends
- Rising adoption of molecular pathology—The growing demand for personalized medicine pushes the adoption of molecular-level diagnostic solutions. In early 2024, NeoGenomics Laboratories introduced an expanded menu of molecular tests to cater to oncology diagnostics.
- Automation and workflow digitization—Laboratory automation and digital pathology systems streamline processes, reduce human error, and increase throughput. Danaher’s Leica Biosystems announced new automation modules in March 2024 to address high laboratory workloads.
Key Opportunities
- Expansion of telepathology services—The increased reliance on remote diagnostics and telemedicine presents an opportunity for market expansion, particularly in rural regions. PathAI, in collaboration with Quest Diagnostics, announced a scalable telepathology solution in April 2024.
- Emergence of companion diagnostics—The rise in targeted therapies boosts the need for companion diagnostic assays. Agilent Technologies partnered with several pharma companies in May 2024 to co-develop companion diagnostic solutions for cancer indications.
Key Challenges
- Shortage of skilled pathologists—The limited number of qualified professionals creates a bottleneck in diagnostic service supply, as highlighted by Laboratory Corporation of America’s March 2024 report on workforce gaps in North American labs.
- High cost of advanced pathology equipment—Substantial initial investment in digital and automated pathology infrastructure can be prohibitive for small and medium-sized labs, as noted in BD’s Q2 2024 financial disclosures.
Key Restraints
- Regulatory complexities and delays—Stringent regulatory approval requirements for new technologies may slow down market entry, as seen in Hologic’s delayed product launches in early 2024.
- Data security and integration issues—Concerns regarding data privacy and interoperability challenge the seamless implementation of digital pathology platforms. PerkinElmer cited these as key barriers during a health technology convention in June 2024.
North America Anatomic Pathology Market Share by Type, 2025
In 2025, services are expected to lead the market share in North America’s anatomic pathology sector, driven by outsourcing trends and the growing need for specialized diagnostic interpretations. Instruments and consumables also maintain significant presence, reflecting ongoing laboratory upgrades and increased test volumes. Reagents, kits, and other categories underscore the diversification of the market’s product mix, enabling advanced pathology workflows. The growing focus on core diagnostic services will ensure sustained demand for both consumables and instruments throughout the forecast period.
North America Anatomic Pathology Market Share by Applications, 2025
Disease diagnosis dominates the application segment within the North America anatomic pathology market, reflecting a heightened focus on cancer screening and early detection of chronic diseases. Drug discovery and development also represents a significant portion, as pharmaceutical R&D depends heavily on anatomic pathology for biomarker validation and patient stratification. Research, cytopathology, surgical pathology, and hematopathology, while forming smaller slices of the pie, collectively illustrate the diverse utility of pathology across medical disciplines. The sustained emphasis on diagnostic precision and research innovation will continue driving these applications forward.
North America Anatomic Pathology Market Revenue (USD Million), 2020-2035
The market is projected to exhibit consistent revenue growth from 2020 to 2035, with the total reaching 7,860 Million USD in 2025. This upward trend is primarily attributed to rising chronic disease incidences, technological advancements, and expanding application scope in diagnostics and research. Investment in digital pathology, automation, and molecular diagnostics solutions is poised to accelerate revenue generation through the forecast period.
North America Anatomic Pathology Market YOY Growth (%), 2020-2035
Year-over-year growth in the North America anatomic pathology market is set to remain strong between 2020 and 2035, with the YOY growth rate peaking at 8.8% in 2025. Following this, the market maintains healthy single-digit growth through the forecast period, reflecting sustained technology upgrades and increased healthcare spending. YOY fluctuations indicate market responses to developments in cancer screening, molecular diagnostics, and laboratory automation.
North America Anatomic Pathology Market Share by Country, 2025
The United States will retain the largest regional share in 2025, accounting for 78% of the North America Anatomic Pathology Market owing to its advanced healthcare infrastructure, strong funding for R&D, and higher adoption rates of advanced pathology technologies. Canada follows with 13% share, benefiting from national cancer control initiatives and a growing emphasis on lab automation. Mexico holds a 9% share, with rising investments in healthcare modernization and an expanding diagnostic services network.
North America Anatomic Pathology Market Top Players Share, 2025
F. Hoffmann-La Roche Ltd. holds the largest share among market players in 2025, driven by regular innovation and a comprehensive pathology product portfolio. Danaher Corporation, Thermo Fisher Scientific, Agilent Technologies, and Sakura Finetek remain key contributors, bolstered by acquisitions and product expansions. The competitive landscape is characterized by a blend of multinational giants and specialized niche firms.
North America Anatomic Pathology Market Buyers Share, 2025
Hospitals account for the largest share of buyers in the North America anatomic pathology market as they conduct the majority of diagnostic procedures and complex tissue analysis. Diagnostic laboratories represent a significant share, with retail and direct tender segments following. Increasing adoption of specialized pathology services is fostering higher procurement by both hospitals and independent labs.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | 7860 |
| Regions | US, Canada, Mexico |
| Segments | By Type, By Application, By Distribution Channel, By Technology, By Organization Size |
| Players | F. Hoffmann-La Roche Ltd., Danaher Corporation, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Sakura Finetek USA, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., BioGenex Laboratories, Merck KGaA, Abbott Laboratories, Hologic, Inc., BD (Becton, Dickinson and Company), PerkinElmer Inc., Trivitron Healthcare |
Key Recent Developments
- June 10, 2024: Roche launches new AI-enabled digital pathology platform enhancing clinical workflow automation.
- July 3, 2024: Quest Diagnostics and PathAI unveil remote telepathology diagnostic network across North America.
- August 12, 2024: Agilent Technologies partners with multiple pharma companies to expand companion diagnostics portfolio.
- September 1, 2024: NeoGenomics Laboratories adds next-generation molecular tests to its oncology diagnostic suite.
- October 2, 2024: Danaher Corporation's Leica Biosystems introduces fully automated anatomic pathology lab modules.
